Hinge Health (NYSE:HNGE) Stock: Insider Daniel Antonio Perez Sells 4,100 Shares

Posted by George Bondi on Oct 10th, 2026

Hinge Health Inc. (NYSE:HNGE – Get Free Report) CEO Daniel Perez sold 4,100 shares of Hinge Health stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $100.20, for a total value of $410,820.00. Following the sale, the chief executive officer owned 4,100 shares in the company, valued at $410,820. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Antonio Perez also recently made the following trade(s):

On Thursday, September 10th, Daniel Perez sold 150,000 shares of Hinge Health stock. The shares were sold at an average price of $89.44, for a total value of $13,416,000.00.
On Thursday, September 10th, Daniel Perez sold 100,000 shares of Hinge Health stock. The stock was sold at an average price of $89.45, for a total value of $8,945,000.00.

Hinge Health Stock Up 4.9%

HNGE opened at $102.82 on Friday. Hinge Health Inc. has a 52 week low of $30.08 and a 52 week high of $103.28. The business’s 50 day moving average is $91.24 and its two-hundred day moving average is $71.21. The firm has a market cap of $8.30 billion, a price-to-earnings ratio of 80.33 and a beta of 1.37.

Hinge Health (NYSE:HNGE – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.31. The business had revenue of $212.82 million for the quarter. Hinge Health had a net margin of 15.15% and a return on equity of 51.60%. The business’s revenue was up 53.0% on a year-over-year basis. During the same quarter last year, the business posted $0.59 earnings per share. Equities analysts expect that Hinge Health Inc. will post 1.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Hinge Health

A number of hedge funds have recently added to or reduced their stakes in the company. 11.2 Capital Management LLC acquired a new position in Hinge Health during the 2nd quarter worth approximately $204,566,531. Wellington Management Group LLP raised its stake in shares of Hinge Health by 169.7% during the 2nd quarter. Wellington Management Group LLP now owns 1,205,584 shares of the company’s stock worth $100,063,000 after buying an additional 758,594 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Hinge Health by 225.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,163,187 shares of the company’s stock valued at $44,852,000 after buying an additional 806,007 shares during the period. Alkeon Capital Management LLC boosted its stake in shares of Hinge Health by 110.4% in the fourth quarter. Alkeon Capital Management LLC now owns 791,104 shares of the company’s stock valued at $36,747,000 after buying an additional 415,093 shares in the last quarter. Finally, Estuary Capital Management LP purchased a new stake in shares of Hinge Health in the first quarter valued at approximately $15,201,000.

Analyst Ratings Changes

Several brokerages have recently weighed in on HNGE. Raymond James Financial increased their target price on shares of Hinge Health from $70.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, June 15th. Stifel Nicolaus boosted their price target on Hinge Health from $96.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. Wall Street Zen cut Hinge Health from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded Hinge Health from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday. Finally, Needham & Company LLC upped their price target on Hinge Health from $97.00 to $115.00 and gave the stock a “buy” rating in a research note on Wednesday, September 30th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $105.33.

View Our Latest Stock Analysis on Hinge Health

About Hinge Health

(Get Free Report)

Hinge Health, Inc is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care designed to help members manage pain, improve mobility and avoid or delay more invasive treatments.

Its platform combines a mobile application, motion-sensing technology, personalized exercise therapy, education and support from a care team that may include clinical specialists. Hinge Health offers programs for conditions such as chronic back pain, knee pain and other common MSK issues, with services generally provided through employers, health plans and other healthcare organizations.

Hinge Health was founded in 2015 and is headquartered in San Francisco, California.